Colonoscopy significantly reduces mortality from colorectal cancer in Veterans Affairs study

March 12, 2018, American College of Physicians

Colonoscopy was associated with a 61 percent reduction in colorectal cancer mortality among veterans receiving care through the Veterans Affairs (VA) health system. The reduction was observed for both left- and right-sided colorectal cancer, although the association was weaker for right-sided cancer (46 percent versus 72 percent reduction). The findings are published in Annals of Internal Medicine.

Colonoscopy is widely used in the VA health care system, where it is endorsed as a primary colorectal cancer screening option for average-risk aged 50 and older. Despite its increased use, it is not known whether decreases colorectal cancer mortality among veterans and whether the effect varies based on the anatomical location of colorectal cancer.

A team of researchers from the VA Medical Centers in Indianapolis and White River Junction (affiliated with Indiana University School of Medicine and Geisel School of Medicine in Dartmouth) reviewed VA-Medicare administrative data, and identified 4,964 case patients who were diagnosed with colorectal cancer between 2002 and 2008 and died of the disease by the end of 2010. Case patients were matched to 4 control patients (n = 19,856) without prior diagnosis of colorectal cancer. Exposure to colonoscopy was determined from 1997 to 6 months before colorectal cancer diagnosis in case patients and to a corresponding date in control patients. Subgroup analysis was performed for patients who had undergone screening colonoscopy.

The researchers found that the patients who died of colorectal cancer were significantly less likely to have undergone any colonoscopy. Colonoscopy was associated with reduced mortality for left-sided cancer and right-sided cancer, although the reduction was smaller for right-sided . The authors suggest that reducing variability in colonoscopy effectiveness, particularly against right-sided , is critical for effective disease prevention.

Explore further: Adding surveillance to FIT screening cuts CRC mortality

More information: Annals of Internal Medicine (2018). http://annals.org/aim/article/doi/10.7326/M17-0723

Related Stories

Adding surveillance to FIT screening cuts CRC mortality

October 3, 2017
(HealthDay)—Adding surveillance to fecal immunochemical test (FIT) screening reduces colorectal cancer (CRC) mortality and increases colonoscopy demand, according to a study published online Oct. 2 in the Annals of Internal ...

Support for fecal testing in familial colorectal cancer screening

October 29, 2014
Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, ...

Cancers caught during screening colonoscopy are more survivable

July 13, 2015
Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test, according to a study in the July issue of ...

Patients with positive fecal screening test, sooner is better for colonoscopy

April 25, 2017
The risk of colorectal cancer increased significantly when colonoscopy was delayed by more than nine months following a positive fecal screening test, according to a large Kaiser Permanente study published today in the Journal ...

Recommended for you

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.